Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

Fig. 1

Treatment patterns in first (panel a) and second line (panel b) -n = 178; from chart review. Aromatase inhibitors: anastrozole, letrozole, exemestane and anastrozole + exemestane. Chemotherapy: capecitabine, docetaxel, paclitaxel, paclitaxel + carboplatin, docetaxel + cyclophosphamide, 5 fluorouracil, carboplatin, carboplatin + gemcitabine, cyclophosphamide + doxorubicin, docetaxel + carboplatin, goserelin, nab- paclitaxel. Other: tamoxifen, fulvestrant, everolimus + exemestane, anastrozole + paclitaxel, anastrozole + fulvestrant, anastrozole + tamoxifen, anastrozole + docetaxel, bevacizumab, letrozole + fulvestrant, anastrozole + anthracycline + cyclophosphamide, anastrozole + paclitaxel + anthracycline, bevacizumab + anastrozole + tamoxifen, everolimus, everolimus + letrozole, everolimus + tamoxifen, exemestane + carboplatin, letrozole + zoledronic acid, letrozole + paclitaxel, tamoxifen + goserelin, vinorelbine + lapatinib, lapatinib, toremifene-citrate. Note: “Other” refers to other treatments than aromatase inhibitors and chemotherapy agents

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us